Proteinaceous Molecules Mediating Bifidobacterium-Host Interactions

Lorena Ruiz 1, Susana Delgado 2, Patricia Ruas-Madiedo 2, Abelardo Margolles 2 and Borja Sánchez 2

1 Department of Nutrition, Food Science and Food Technology, Universidad Complutense de Madrid, Spain, 2 Department of Microbiology and Biochemistry of Dairy Products, Instituto de Productos Lácteos de Asturias-Consejo Superior de Investigaciones Científicas, Villaviciosa, Spain

Bifidobacteria are commensal microorganisms found in the gastrointestinal tract. Several strains have been attributed beneficial traits at local and systemic levels, through pathogen exclusion or immune modulation, among other benefits. This has promoted a growing industrial and scientific interest in bifidobacteria as probiotic supplements. However, the molecular mechanisms mediating this cross-talk with the human host remain unknown. High-throughput technologies, from functional genomics to transcriptomics, proteomics, and interactomics coupled to the development of both in vitro and in vivo models to study the dynamics of the intestinal microbiota and their effects on host cells, have eased the identification of key molecules in these interactions. Numerous secreted or surface-associated proteins or peptides have been identified as potential mediators of bifidobacteria-host interactions and molecular cross-talk, directly participating in sensing environmental factors, promoting intestinal colonization, or mediating a dialogue with mucosa-associated immune cells. On the other hand, bifidobacteria induce the production of proteins in the intestine, by epithelial or immune cells, and other gut bacteria, which are key elements in orchestrating interactions among bifidobacteria, gut microbiota, and host cells. This review aims to give a comprehensive overview on proteinaceous molecules described and characterized to date, as mediators of the dynamic interplay between bifidobacteria and the human host, providing a framework to identify knowledge gaps and future research needs.

Keywords: Bifidobacterium, host interaction, proteome, immunomodulation, adhesin

INTRODUCTION

The human gut is inhabited by a trillion of microorganisms which constitute the gut microbiota. These microorganisms are in close contact with the intestinal mucosa, which represents the largest extension of the human body exposed to external stimuli. A complex molecular interplay is established among microbiota, dietary components and host cells, which regulates immune and metabolic functions in the host (Furusawa et al., 2015). Dysbiosis, defined as changes in the gut microbiota structure associated to healthy individuals, disrupts the microbiome-host cross-talk homeostasis and correlates with metabolic and inflammatory disorders (Evans et al., 2013; Patel et al., 2013; Levy et al., 2015).

Pro- and pre-biotics can improve host health through microbiota modulation and immune system boosting (Picard et al., 2005). Some strains of bifidobacteria, which are among the first colonizers of the human intestine and one of the dominant groups in the breast-fed infant
microbiota (Garrido et al., 2012), have been attributed several health benefits, encouraging interest in their use as probiotics. Pathogen inhibition and diarrhea amelioration are their best established outcomes and have been related to the production of organic acids (Fukuda et al., 2011), antibacterial peptides (Moroni et al., 2006), quorum-sensing inhibitors (Cotar et al., 2010), pathogen displacement (Ruas-Madiedo et al., 2006), and virulence attenuation (Tanner et al., 2016). Bifidobacteria also regulate host functions and ferment complex polysaccharides from our diet (Ménard et al., 2005; Heuvelin et al., 2009, 2010; Bermudez-Brito et al., 2013; Furusawa et al., 2015), although there is still limited knowledge on the molecular mechanisms triggering these effects.

Delineating the specific molecules mediating Bifidobacterium cross-talk with the host, will help to understand their beneficial effects and establish microbiome-targeted therapies for human diseases. This review gives an overview on molecules behind the bifidobacterial-host cross-talk, providing a framework to design safe and efficacious probiotic-derived supplements (Licciardi et al., 2010; Shenderov, 2013).

INTESTINAL MUCOSA ADHESION

Bacterial adhesion to the intestinal surface is mediated by non-specific, hydrophobic or electrostatic interactions, and specific mechanisms involving macromolecular interactions between bacterial and host receptors. Functionally characterized Bifidobacterium adhesins, surface-associated proteins that facilitate bifidobacteria attachment to intestinal cells and/or the extracellular matrixes surrounding them, are reviewed below and summarized in Figure 1.

Involvement of pili in bifidobacterial adhesion has been studied in Bifidobacterium bifidum and Bifidobacterium breve (O’Connell Motherway et al., 2011b; Turroni et al., 2013). The B. bifidum PRL2010 genome harbors three pilus clusters. Of these, pil2 and pil3, encode putative sortase-dependent pili that are expressed under both in vitro and in vivo conditions. Heterologous expression of pil3 in Lactococcus lactis significantly increased this bacteria adhesion to the human epithelial cell line Caco-2 (Turroni et al., 2013). The type IVb tight adherence (Tad) pilus-encoding gene cluster from B. breve UCC2003, was found to be essential for the colonization of, and persistence in, the murine gut. Tad inactivation impaired the strain ability to stably colonize the murine intestine, as reflected by reduced shedding level and bifidobacterial numbers in the gut (O’Connell Motherway et al., 2011b). Another surface-anchored protein potentially involved in intestinal adhesion of bifidobacteria is BopA. This purified lipoprotein competes with B. bifidum MIMBb75 adhesion to Caco-2 cells, and probably facilitates B. bifidum adhesion (Guglielmetti et al., 2008). Indeed, Bifidobacterium strains overexpressing bopA adhere better (Gleinser et al., 2012). However, B. bifidum treatment with anti-BopA antibodies does not reduce the attachment to intestinal cells (Kainulainen et al., 2013), thus the specific adhesion mechanism mediated through BopA must be further elucidated.

Remarkably, bifidobacteria can use some moonlighting proteins, those with multiple functions (Jeffery, 2003), as adhesin-like factors. Surface-exposed glycolytic enzymes, including transaldolase from B. bifidum and enolase from Bifidobacterium animalis, are adhere to mucin and plasminogen, respectively (Candela et al., 2009; González-Rodríguez et al., 2012). Other surface-exposed moonlighting proteins, including the chaperone DnaK from B. animalis and the elongation factor Tu from Bifidobacterium longum, showed high affinity for human plasminogen in vitro and have been proposed as mediators of intestinal attachment (Candela et al., 2010; Wei et al., 2014).

It is worth highlighting that most of the adhesins herein described have been identified on in vitro assays and their relevance for intestinal colonization has not been tested in vivo. Since laboratory models do not accurately mimic all the factors that can affect bacterial attachment to the intestinal mucosa (e.g., due to the absence of a mucus layer and resident microbiota), functional confirmation of the adhesion capacity in vivo is still required (Ouwehand and Salminen, 2003).

TIGHT-JUNCTIONS

A single layer of epithelial cells provides a selective barrier separating intestinal lumen from subjacent tissues. Tight-junctions (TJ) are multi-protein complexes that control molecule translocation across this barrier (Lee, 2015), and their disruption leads to uncontrolled trafficking of noxious molecules triggering inflammation (Bergmann et al., 2013).

Specific Bifidobacterium strains promote TJ enhancing epithelial barrier integrity (Ohland and Macnaughton, 2010; Mokkala et al., 2016). In animal models, B. bifidum and B. longum strains preserved TJ localization, attenuating intestinal permeability, and decreasing necrotizing enterocolitis incidence (Khailova et al., 2009; Bergmann et al., 2013; Srtukova et al., 2015). Preliminary work suggested that B. bifidum metabolites, like acetate, induced TJ expression in intestinal cells (Hsieh et al., 2015). Soluble factors present in B. longum lysates or secreted by B. infantis or B. breve strains, also mediate epithelial barrier maintenance (Ménard et al., 2005; Ewaschuk et al., 2008; Sultana et al., 2013). Further research to identify the specific molecules mediating this TJ promotion is needed.

MUCUS, HMO, AND NON-DIGESTIBLE CARBOHYDRATES DEGRADATION

The spatial distribution of bacteria throughout the gastrointestinal tract, is partly controlled by nutrients availability for resident microbiota (Donaldson et al., 2016). Indeed, our wellbeing relates with the nutrient harvesting capability of our gut microbes. These microorganisms, overall, can utilize dietary and host carbohydrates, and glycans produced by other gut bacteria. Indeed, 89 “carbohydrate active enzymes” (CAZyme) have recently been identified in 85% of the microbiomes obtained from 488 individuals (Bhattacharya et al., 2015), suggesting that gut bacteria are highly specialized in using available glycans as
their main sustenance. Bifidobacterial genomes are abundant in saccharolytic features whose expression is tightly regulated by available carbohydrates (Khoroshkin et al., 2016), supporting that host glycans were a potent evolutionary force driving their successful gut colonization (Sánchez et al., 2013; Milani et al., 2016).

Numerous studies demonstrated bifidobacteria’s capability to use dietary non-digestible oligosaccharides, which is on the basis of the prebiotic concept (Rastall and Gibson, 2015). Glycosyl hydrolases (GH, or glycosidases), many of which are extracellular, have high specificity for the oligosaccharides constituents and cleave the glycosidic bonds (Table 1). Special attention has been paid to the GH acting on human milk oligosaccharides (HMO) since these serve as substrates for bifidobacteria, which are the initial gut colonizers in breast-fed infants. HMO are structurally diverse and composed of several monosaccharides (glucose, galactose, N-acetylglucosamine, fucose, or sialic acid). They mainly consist of a lactose core linked to units (α = 0–15) of lacto-N-biose (type I) or to N-acetyllactosamine (type II; Smilowitz et al., 2014). Bifidobacteria secrete GH that cleave specific linkages within the HMO molecules and the best characterized are those synthesized by B. bifidum which, together with B. longum subsp. infantis, are two abundant species in breast-fed neonates (Table 1). These species employ different strategies for HMO utilization. Whereas B. bifidum has an array of membrane-associated GH, B. longum subsp. infantis is specialized in the import and intracellular breakdown of HMO (Garrido et al., 2013; Jae-Han et al., 2013). Moreover B. longum strains have similar HMO-utilization patterns, whilst B. bifidum strains are more diverse with some unable to use fucosylated or sialylated HMO (Garrido et al., 2015). Similarly, the B. breve HMO utilization profile is strain dependent and, contrary to B. bifidum, some strains consume fucosylated or sialylated HMOs. B. breve's capability to use these HMOs explains its abundance in breast-fed babies (Ruiz-Moyano et al., 2013).

Some bifidobacteria can also utilize mucins from the mucus layer coating the intestine. Mucin composition and structure resemble that of HMO; consisting of a core of different O-glycans, built on α- and β-linked N-acetyl-galactosamine, galactose, and N-acetyl-glucosamine residues, which can incorporate fucose and sialic acid residues (Tailford et al., 2015). B. longum and B. breve strains’ capability to effectively use mucin carbohydrates, has been confirmed in vitro (Ruas-Madiedo et al., 2008). However, GH able to degrade mucins have only been described in B. bifidum (Table 1). Indeed, in a comparative genomic study 60% of the GH-encoding genes from B. bifidum were predicted to breakdown mucin-like glycans and most of them were exclusively present in this bifidobacterial species (Turroni et al., 2014). Remarkably, other species could use the mono- and oligosaccharides released by B. bifidum GH thus evidencing the existence of cross-feeding mechanisms, as it has been demonstrated in B. breve and B. bifidum co-cultures (Egan et al., 2014).

Bifidobacterium capacity to metabolize specific dietary and host-derived carbohydrates is also dependent on the presence of specific sugar transport systems. These are crucial for their competitive establishment in the gut, thus representing one of the molecular mechanisms by which bifidobacteria interact with the host. Import sugar mechanisms in bifidobacteria are herein described (Bottacini et al., 2014).

First, ATP-binding cassette (ABC) systems are active transporters which couple ATP hydrolysis to translocation uptake across the cell membrane. They are the most frequent sugar transporters in bifidobacteria and have been described for mono- and oligosaccharides in different species (Nishimoto and Kitaoka, 2007; Wada et al., 2008; Wei et al., 2012), although only a few of them have been functionally characterized at protein level (Suzuki et al., 2008; Ejby et al., 2013).

Secondly, some secondary transporters, predicted to consist of single integral membrane-associated proteins, have been characterized at protein level in bifidobacteria. These include permease systems for the uptake of lactose, glucose, and sucrose (Parche et al., 2006). Secondary transporters encoding genes have been identified in different bifidobacterial species, although most of them have not been characterized at protein level (Turroni et al., 2012).

Proton symporters of the glycose-pentose-hexuronide (GPH) cation symporter family for melibiose and pentosides were also described in Bifidobacterium (Lee and O’Sullivan, 2010; Turroni et al., 2012), although they remain to be characterized.

Finally, phosphoenolpyruvate-phosphotransferase (PEP-PTS) systems were first characterized in the 90’s in B. breve and B. bifidum at protein level (Lee and O’Sullivan, 2010). Later, genome sequence availability revealed their wide spread distribution in bifidobacteria. In particular, B. breve UCC2003 genome contains four PEP-PTS systems, one of which has been characterized as a fructose-specific transporter (Mazé et al., 2007). Also, in silico analysis revealed a putative glucose-specific PEP-PTS uptake system in B. longum (Lorca et al., 2007). However, genome analysis of different B. longum strains showed that glucose-specific PTS transporters are minor in comparison with ABC transporters (Pokusaeva et al., 2011), thus glucose may be transported preferentially by secondary permeases (Parche et al., 2006).

Comparative genomic analysis revealed that sugar PEP-PTS systems are present in all bifidobacterial genomes, except for B. animalis subsp. lactis (Lee and O’Sullivan, 2010) which is hypothesized to have lost most of their carbohydrate transporters due to extended cultivation under industrial conditions. In fact, the capability to utilize variable carbon sources is considered an adaptation to the gut environment. For instance, the dominant Bifidobacterium species in infant fecal samples (B. longum and B. bifidum) is consistent with their inherent ability to use host-derived oligosaccharides such as mucin and HMO (Bottacini et al., 2014), and their possession of a wide range of host-derived carbohydrate transporters, such as those involved in N-biose import (Suzuki et al., 2008).

REGULATION T-EFFECTOR CELLS
AND T_reg

In the absence of disease, the ensemble of molecular interactions taking place in the human gut results in
| Substratea | Glycosyl hydrolase (family) | Bifidobacteria species | References |
|------------|-----------------------------|------------------------|------------|
| a-glycans: palatinose (1→6); turanose (1→3); maltotriose and maltose (1→4) linkages, etc. | α-1,6-glucosidase (GH13) | B. breve UCC2003 | Pokusaeva et al., 2009; Kelly et al., 2016 |
| Starch and starch-like carbohydrates (pullulan, maltodextrin, etc.) | α-amylases, amylopullulanases, etc. | B. adolescentis 22L | Duranti et al., 2014 |
| Starch hydrolysates (maltodextrins, malto-OS, isomalto-OS, maltose, etc.) | α-glucosidases, α-amyloses, etc. | B. longum subsp. longum BBMN68 | Liu et al., 2015 |
| Plant ginsenoside and cellobiose | β-glucosidase (GH1, GH3) | B. animalis subsp. lactis AD011 | Kim et al., 2012 |
| Isoflavone glycosides (daidzin) | β-glucosidases (GH3) | B. pseudocatenulatum IPLA36007 | Alegría et al., 2014 |
| β-glucosides (mycotoxins from cereal-based foods) | β-glucosidases | B. adolescentis DSM20083 | Michlmayr et al., 2015 |
| β-galactans, β-galacto-OS: (1→4) linkages Endogalactanase (GH53) | | B. longum NCC2705 | Hinz et al., 2005 |
| β-galactans (potato) | β-1,4-endogalactanase | B. breve UCC2003 | O’Connell Motherway et al., 2011a |
| β-1,3-galactooligosaccharides and arabino-galactan | exo-β-1,3-galactanase | B. longum JCM1217 | Fujita et al., 2014 |
| Arabinofuranohydrolase | B. adolescentis DSM20083 | van den Broek et al., 2005 |
| β-L-arabinofuranosides | β-L-arabinobiosidase (GH121) | B. longum JCM 1217 | Fujita et al., 2011 |
| α-1,5-linked arabinono-OS | α-L-arabinofuranosidase (GH1) | B. adolescentis ATCC 15703 | Suzuki et al., 2013 |
| Plant ginsenoside | β-D-xilosidase | B. breve K-110 | Hyun et al., 2012 |
| Xylo-OS | β-D-xilosidase (GH43) | B. animalis subsp. lactis BB-12 | Viborg et al., 2013 |
| β-(2,1) in short-chain inulin-type fructans, Raffinose | β -fructofuranosidase (GH32) | B. longum KN29.1 | Bujacz et al., 2011 |
| Flavonoid rhamnoglycosides: (1→6) linkage | α-L-rhamnosidase | B. dentium | Bang et al., 2015 |
| β-Mannans (plants) | Mannanase (GH5_8) | B. animalis subsp. lactis BI-04 | Morrill et al., 2015 |
| Human carbohydrates: MUCIN and HMO | | | |
| α-L-Fucosyl termini residues from glycoconjugates | 1,2-α-L-fucosidase (GH96) | B. bifidum JCM1254 | Katayama et al., 2004 |
| Mucin-OS (Core 1 type O-glycans) | Endo-α-N-acetylglactosaminidase (GH101) | B. longum JCM 1217 | Fujita et al., 2005 |
| Mucin 2 (Core 3 type O-glycans) | α-N-acetylglactosaminidase (GH129) | B. bifidum JCM1254 | Kyochara et al., 2012 |
| Gastrodoudonal mucin (terminal GlcNAc1→4Gal) | α-N-acetylgalcosaminidase (GH89) | B. bifidum JCM1254 | Shimada et al., 2015 |
| HMO and lacto-N-tetraose (type I chain) | Lacto-N-biosidase (GH20) | B. bifidum JCM1254 | Wada et al., 2008 |
| HMO α1,3/4-fucosylated OS | 1,3–1,4-α-L-fucosidase | B. bifidum JCM1254 | Ashida et al., 2009; Ito et al., 2013 |
| HMO and lacto-N-neotetraose (type II chain) | β-galactosidase + β-N-acetyhexosaminidases | B. bifidum JCM1254 | Miwa et al., 2010 |
| HMO sialylOS | Exo-α-sialidase (GH33) | B. bifidum JCM1254 | Kyochara et al., 2011 |
| Fucosylated HMO | α-L-fucosidases (GH29, GH95) | B. longum subsp. infantis ATCC15697 | Sela et al., 2011 |
| HMO (type I chain) + (type II chain) | β-1,3-galactosidases + β-galactosidase | B. longum subsp. infantis ATCC15697 | Yoshida et al., 2012 |

(Continued)
TABLE 1 | Continued

| Substratea | Transporter Family | Bifidobacteria species | References |
|------------|-------------------|------------------------|------------|
| Arabinoxylo-OS | ABC transporter | *Bifidobacterium* subsp. *lactis* BI-04 | Ejby et al., 2013 |
| Xylo-OSs | ABC transporter | *B. animalis* subsp. *lactis* BB-12 | Gilad et al., 2010 |
| Galacto-OS | ABC transporter | *B. breve* | O’Connell Motherway et al., 2011a |
| β-glucans | ABC transporter | *B. longum* subsp. *infantis* | Zhao and Cheung, 2013 |
| Galacto-OS, HMO, fructo-OS | ABC transporter | *B. longum* subsp. *infantis* ATCC15697 | Kim et al., 2012 |
| HMOs, inulin, Galacto-OS | ABC transporter | *B. longum* subsp. *infantis* ATCC15697 | Garrido et al., 2011 |
| galacto-N-biose/facto-N-biose | ABC transporter | *B. longum* JCM1217 | Wada et al., 2007 |
| 4′-galactosylactose | ABC transporter | *B. breve* Yakult | Shigehisa et al., 2015 |
| Cellobiose, galacto-OS, isomaltose, maltotriose, melibiose, panose, raffinose, stachyose, xylobiose β-xylo-OS | ABC transporter(ers) | *B. lactis* BI-04 | Andersen et al., 2013 |
| Lacto-N-biose, galacto-N-biose | ABC-transporter | *B. longum* JCM1217 | Suzuki et al., 2008 |
| Fructose | ABC-transporter | *B. longum* NCC2705 | Liu et al., 2011; Wei et al., 2012 |
| Ribose | ABC transporter | *B. breve* UCC2003 | Pokusaeva et al., 2010 |
| Glucose | Secondary transporter | *B. animalis* DSMZ10140 | Briczinski et al., 2008 |
| Fructose | PTS | *B. breve* UCC2003 | Mazé et al., 2007 |
| Glucose | PTS | *B. longum* NCC2705 | Parche et al., 2007 |
| Glucose | PTS | *B. longum* NCC2705 | Parche et al., 2006 |
| Glucose | PTs | *B. animalis* subsp. *lactis* | Briczinski et al., 2008 |

SUGAR TRANSPORTERS

β-glucans, oligosaccharide(s).

Human carbohydrates: mucin and HMO.

PTS, phosphotransferase system.

the intestinal homeostasis. Specialized epithelial cells denominated M-cells and antigen presenting cells (APCs) from the gut-associated lymphoid tissue (GALT) continuously sample the intestinal content. Interaction of APCs with the rest of GALT effectors, mainly T and B cells, leads to immunotolerance against commensal microbes and dietary components, whilst the capacity of mounting an acute, quick, and powerful response against enteropathogens is developed.

Differentiation of commensal and pathogenic bacteria is based on the presence of pattern recognition receptors (PRRs) on the APC and epithelial cell surfaces. Among them, Toll-like receptors, NOD-like receptors, C-type lectin receptors, and RIG-I-like receptors are in charge of recognizing specific microbial-associated molecular patterns (MAMPs), such as flagellin, teichoic acids, or lipopolysaccharide among others. The type and intensity of the downstream and intracellular signaling cascades deployed after MAMPs-PRR interaction is essential for the APCs interaction with T-cells, which will finally determine the nature of the T-cell response. Roughly, T-cell responses are divided into effector (Th1/Th2) and regulatory (Treg), its balance being key in the intestinal homeostasis maintenance (Maloy and Powrie, 2011). It is generally accepted that commensal microbiota, by inducing Treg response, modulates the Th1/Th2 balance favoring immune tolerance against the gut microbiota (Ventura et al., 2012). Indeed, the classical MAMP triggering Treg response is the exopolysaccharide A of the commensal bacterium *Bacteroides fragilis*, molecule also involved in the GALT maturation (Mazmanian et al., 2008).

Bifidobacteria may drive species-specific T-cell responses, as it was revealed by a series of experiments in which the cytokine secretion profiles of monocyte-derived dendritic cells (MoDCs) and full fractions of peripheral blood mononuclear cells (PBMCs) were determined (López et al., 2010). Relative levels of key cytokines (IL-10, IL-17, TNFα among others) suggested a specific immunomodulation mechanism for each species, as reported recently for probiotics (Hill et al., 2014). Challenging immature MoDCs with different strains, followed by co-culture with allogeneic naïve CD4+ cells and cytokine determination, further confirmed this effect (López et al., 2011).

Remarkably, *B. bifidum* LMG13195 appeared to induce a Treg response in vitro (Figure 1; López et al., 2011). Dendritic cells challenged with membrane vesicles from this strain induced naïve CD4+ cells polarization into Treg, as deduced from the increases in the expression of *foxP3* regulation factor and the CD25 marker (López et al., 2012). Most likely, surface-associated proteins play a role in this process. Several proteins have been identified in the bifidobacterial membrane, among which moonlighting proteins such as fructose-6-phosphate phosphoketolase or enolase, might be behind the immunomodulatory effects of the membrane vesicles (Sánchez et al., 2004). However, the particular proteins involved in this T-cell polarization have not been identified.
FIGURE 1 | (A) Schematic representation of the bifidobacterial proteins identified as key mediators of the cross-talk mechanisms with the intestinal environment. Adhesin-like factors, proteins with immunomodulatory capabilities and glycosyl hydrolases specific for carbon sources encountered in the gastrointestinal tract are represented. (B) Graphical illustration of the immunomodulatory mechanisms driven by model Bifidobacterium bifidum strains. Different B. bifidum fractions and molecules induces $T_{\text{reg}}$ response, key in maintaining the balance of effector T-cell responses. Membrane vesicles or the extracellular protein TgaA affects dendritic cells, which induces $T_{\text{reg}}$ differentiation after interaction with naïve T-cells. In this process, increased IL-10 secretion, recognition of CD80, and CD86 by CD28 in naïve T-cells and release of IL-2 are key for $T_{\text{reg}}$ response development.

Other immunogenic extracellular proteins are pili, proteinaceous structures that self-assemble into filaments on the bacterial surface (Ventura et al., 2012). Specifically, one sortase-dependent pil from B. bifidum PRL2010 induced TNFα production during transient colonization of the murine mucosa, which acted as a macrophage-activating factor during Th1 (Turroni et al., 2013). Another surface-protein able to influence T-cell responses is TgaA from B. bifidum, a peptidoglycan-derived enzyme able to induce DC activation and IL-2 production (Guglielmetti et al., 2014). IL-2 is one of the main cytokines supporting $T_{\text{reg}}$ proliferation, which are characterized by the presence of CD25, the T-cell receptor for that interleukin (Zelante et al., 2012). Despite the evidence supporting an immunomodulation role of bifidobacteria, only a few surface-associated proteins have been identified as possible mediators of this effect on a limited number of in vitro experiments. Identifying the molecules behind this effect and confirming their efficacy in clinical trials, might provide keys to ameliorate diseases characterized by exacerbated immune responses.

INDUCTION OF IgA PRODUCTION

Immunoglobulin A (IgA) is the most abundant antibody in human mucosa and modulates immune responses against commensal bacteria, preventing direct contact with immune cells (Peterson et al., 2007; Brandtzaeg, 2013). Globally, 40% of gut bacteria are IgA-coated although these values are species- and strain-dependent (Talja et al., 2014). In healthy individuals, IgA coating of bifidobacteria is higher than that of other commensals (van der Waaij et al., 2004; De Palma et al., 2010), explaining the immune tolerance to high densities of bifidobacteria. In fact, 44 proteins from B. longum and 24 from B. adolescentis were recognized by IgA (Talja et al., 2014). IgA-coated bifidobacteria also enhanced probiotic attachment to Caco-2 cells and increased production of mucosal defense molecules (Mathias et al., 2010).

Levels of IgA-coated gut commensals are altered in dysbiosis states such as those described in coeliac disease (De Palma et al., 2010), inflammatory bowel disease (van der Waaij et al., 2004), or autoimmunity disorders (Talja et al., 2014). Coeliac children showed reduced levels of bifidobacteria and IgA-coated bacteria (De Palma et al., 2010). Conversely, IgA from children developing islet autoimmunity, bound to more B. adolescentis antigens than those from healthy controls (Talja et al., 2014). Moreover, bifidobacterial supplements modulate IgA production (Holscher et al., 2012; Kandasamy et al., 2014). A probiotic mixture containing bifidobacteria increased IgA and reduced diarrhea following rotavirus vaccination in a gnotobiotic pig model (Kandasamy et al., 2014). B. animalis Bb12 supplementation to formula-fed infants increased IgA in feces and, in those delivered by C-section, enhanced immune responses as reflected by higher anti-rotavirus and anti-poliovirus IgA production following vaccination (Holscher et al., 2012). The bifidogenic effect of galactooligosaccharides also correlated to increased IgA production (Vulevic et al., 2013; Paineau et al., 2014). Further,
research to specifically delineate the bifidobacterial molecules mediating IgA induction and interaction is necessary.

OTHER BIFIDOBACTERIUM EFFECTORS OF THE HOST-MICROBE DIALOGUE

A few extracellular proteins, with important physiological roles not discussed in the previous sections deserve further attention. Some Bifidobacterium strains produce surface-exposed Serine Protease Inhibitors of proteinaceous nature (serpins), which participate in a variety of physiological processes. The serpin produced by B. longum NCC2705 inhibits elastase-like proteases, including neutrophil or pancreatic elastases, thus suggesting a role in protecting bifidobacteria against exogenous proteases and potential anti-inflammatory activity (Ivanov et al., 2006). Remarkably, serpins are widely distributed in bifidobacteria and several species harbor serpin-encoding genes in their genomes (Turroni et al., 2010).

CONCLUSIONS

Some Bifidobacterium proteins have been identified as mediators of the cross-talk bifidobacteria-host, providing bases to understand their beneficial traits and opening new avenues to conceive bifidobacterial-based therapeutic strategies. However, in most cases, the molecular mechanisms triggered remain unknown what has limited their translation into improved functional supplements. Identifying targets for intervention at intestinal level and developing appropriate models to search for bifidobacterial mediators is required to delineate strategies that fine-tune disease-associated alterations in the microbiota-host interplay.

AUTHOR CONTRIBUTIONS

LR, SD, PM, AM, and BS contributed to the design and organization of the manuscript, drafted, reviewed, and accepted the final version of the manuscript.

ACKNOWLEDGMENTS

This research was funded by Grant AGL2013-44039-R from the Spanish “Plan Estatal de I+D+I.” LR has received funding from the People Programme (Marie Curie Actions) of the European Union’s Seventh Framework Programme FP7/2007-2013/ under REA grant agreement n°624773. BS was recipient of a Ramón y Cajal postdoctoral contract from the Spanish Ministry of Economy and Competitiveness. SD is hired on a contract supported by BIO2014-55019-JIN project from the Spanish “Plan Estatal de I+D+I.”

REFERENCES

Alegria, A., Delgado, S., Guadamuro, L., Flórez, A. B., Felis, G. E., Torriani, S., et al. (2014). The genome of Bifidobacterium pseudocatenulatum IPLA 36007, a human intestinal strain with isoflavone-activation activity. Gut Pathog. 6:31. doi: 10.1186/1757-4749-6-31

Andersen, J. M., Barrangou, R., Abou Hachem, M., Lahtinen, S. J., Goh, Y. J., Svensson, B., et al. (2013). Transcriptional analysis of oligosaccharide utilization by Bifidobacterium lactis BI-04. BMC Genomics 14:12. doi: 10.1186/1471-2164-14-312

Ashida, H., Miyake, A., Kiyoohara, M., Wada, J., Yoshida, E., Kumagai, H., et al. (2009). Two distinct α-L-fucosidases from Bifidobacterium bifidum are essential for the utilization of fucosylated milk oligosaccharides and glycoconjugates. Glyobiology 9, 1010–1017. doi:10.1093/glycob/cwp082

Bang, S.-H., Hyun, Y. J., Shim, J., Hong, S.-W., and Kim, D. H. (2015). Metabolism of rutin and poncirin by human intestinal microbiota and cloning of their metabolizing α-L-rhamnosidase from Bifidobacterium dentium. J. Microbiol. Biotechnol. 25, 18–25. doi:10.4014/jmb.1404.04060

Bergmann, K. R., Liu, S. X., Tian, R., Kushnir, A., Turner, J. R., Li, H. L., et al. (2013). Two distinct α-L-fucosidases from Bifidobacterium bifidum are essential for the utilization of fucosylated milk oligosaccharides and glycoconjugates. Glyobiology 9, 1010–1017. doi:10.1093/glycob/cwp082

Bottacin, F., Ventura, M., van Sinderen, D., and O’Connell Motherway, M. (2014). Diversity, ecology and intestinal function of bifidobacteria. Microb. Cell Fact. 13(Suppl. 1):S4. doi: 10.1186/1475-2859-13-S1-S4

Brandtzaeg, P. (2013). Secretory IgA: designed for anti-microbial defense. Front. Immunol. 4:222. doi:10.3389/fimmu.2013.00222

Briczinski, E. P., Phillips, A. T., and Roberts, R. F. (2008). Transport of glucose by Bifidobacterium animalis subsp. lactis occurs via facilitated diffusion. Appl. Environ. Microbiol. 74, 6941–6948. doi:10.1128/AEM.028795-0

Bujacz, A., Jedrzejczak-Krzepkowska, M., Bielecki, S., Redzynia, I., and Bujacz, G. (2011). Crystal structures of the apo form of β-fructofuranosidase from Bifidobacterium longum and its complex with fructose. FEBS J. 278, 1728–1744. doi: 10.1111/j.1742-4658.2011.08098

Candela, M., Biagi, E., Centanni, M., Turroni, S., Vici, M., Musiani, F., et al. (2009). Bifidobacterial enolase, a cell surface receptor for human plasminogen involved in the interaction with the host. Microbiology 155, 3294–3303. doi: 10.1099/mic.0.028795-0

Candela, M., Centanni, M., Fiori, J., Biagi, E., Turroni, S., Orrico, C., et al. (2010). Dnak from Bifidobacterium animalis subsp. lactis is a surface-exposed human plasminogen receptor upregulated in response to bile salts. Microbiology 156, 1699–1618. doi: 10.1099/mic.0.038307-0

Cotar, A. I., Chifiriuc, M. C., Dinu, S., Pelinescu, D., Banu, O., and Lazăr, V. (2010). Quantitative real-time PCR study of the influence of probiotic culture soluble fraction on the expression of Pseudomonas aeruginosa quorum sensing genes. Roum. Arch. Microbiol. Immunol. 69, 213–223.

De Palma, G., Nadal, I., Medina, M., Donat, E., Ribes-Koninckx, C., Calabuig, M., et al. (2010). Intestinal disbiosis and reduced immunoglobulin-coated bacteria associated with coeliac disease in children. BMC Microbiol. 10:63. doi: 10.1186/1471-2180-10-63

Donaldson, G. P., Lee, S. M., and Mazmanian, S. K. (2016). Gut biogeography of the bacterial microbiota. Nature Rev. Microbiol. 14, 20–32. doi: 10.1038/nrmicro3552

Duranti, S., Turroni, F., Bottacin, F., Bottacin, F., Tullmann, M., and O’Connell Motherway, M. (2014). Genomic characterization and transcriptional studies of the starch-utilizing strain Bifidobacterium adolescentis 22L. Appl. Environ. Microbiol. 80, 6080–6090. doi:10.1128/AEM.01993-14
model of necrotizing enterocolitis. Am. J. Physiol. Gastrointest. Liver Physiol. 297, G940–G949. doi: 10.1152/ajpgi.00141.2009

Khoroshkin, M. S., Leyn, S. A., Van Sinderen, D., and Rodionov, D. A. (2016). Transcriptional regulation of carbohydrate utilization pathways in the Bifidobacterium genus. Front. Microbiol. 7:120. doi: 10.3389/fmicb.2016.00120

Kim, Y., Wang, Y., Park, S. J., Ji, G. E., and Park, M. S. (2012). Cloning and expression of β-glucosidases from Bifidobacterium lactis AD011. Food Sci. Biotechnol. 21, 731–738. doi: 10.1007/s10068-012-0095-0

Kiyohara, M., Nakatomi, T., Kurihara, S., Fushinobu, S., Suzuki, H., Tanaka, T., et al. (2012). α-N-acetylgalactosaminidase from infant-associated bifidobacteria belonging to novel glycoside hydrolase family 129 is implicated in alternative mucin degradation pathway. J. Biol. Chem. 287, 693–700. doi: 10.1074/jbc.M111.277384

López, P., González-Rodríguez, I., Gueimonde, M., Margolles, A., and Suárez, A. (2011). UCC2003: a versatile family 3 Glycoside Hydrolase from bifidobacteria. Biotechnol. Bioproc. Eng. 17, 81–86. doi: 10.1007/s12257-011-9307-5

López, P., Gueimonde, M., Margolles, A., and Suárez, A. (2010). Distinct Bifidobacterium strains drive different immune responses in vitro. Int. J. Food Microbiol. 138, 157–165. doi: 10.1016/j.ijfoodmicro.2009.12.023

Mora, L., Cabezudo, P., Suarez, A., and Espejo, J. (2010). Inactivation of Lactobacillus species by a culture of Bifidobacterium animalis subsp. lactis UCC2003. J. Dairy Sci. 93, 5238–5250. doi:10.3178/jd.93.5238

Ohland, C. L., and Macnaughton, W. K. (2010). Probiotic bacteria and intestinal epithelial barrier function. Am. J. Physiol. Gastrointest. Liver Physiol. 298, G807–G819. doi: 10.1152/ajpgi.00243.2009

Parche, S., Beleut, M., Rezzonico, E., Jacobs, D., Arigoni, F., Titgemeyer, F., et al. (2006). Lactose-over-glucose preference in Bifidobacterium longum NCC2705: the role of glucose transporters in the selection of bacterial species and the human gut microbiota. Appl. Environ. Microbiol. 72, 2923–2933. doi: 10.1128/AEM.01886-05

Pichard, C., Fioramonti, J., François, A., Robinson, T., Neant, F., and Mucuchays, C. (2005). Review article: bifidobacteria as probiotic agents — physiological effects and clinical benefits. Aliment. Pharmacol. Ther. 22, 495–512. doi: 10.1111/j.1365-2036.2005.02615.x

Poujol, F., Pernot, C., Vincent, J. P., Falart, C., and Lebeurier, E. (2006). New adhesion and invasion of food-borne Listeria monocytogenes by bacteria-inhibiting Bifidobacterium animalis subsp. lactis. J. Bacteriol. 188, 921–933. doi: 10.1128/JB.188.3.921-933.2006

Puri, R., Dutt, P., and O’Keeffe, S. (2012). Bifidobacterium bifidum LMG13195 as potential adjuvants in immunotherapy. Exp. Biol. Med. 237, 980–991. doi:10.1177/1079298X11425827

Rahman, M. M., Delves-Broughton, J., and O’Kennedy, R. (2004). Transport capabilities of eleven gram-positive bacteria: their implications on inflammatory bowel diseases. Cell Host Microbe 2, 328–339. doi: 10.1016/j.chom.2007.09.013

Rasouli, S., and Zakhour, M. (2011). Oral delivery of probiotics: improving survival and adhesion to intestinal epithelium. Front. Microbiol. 2:8. doi: 10.3389/fmicb.2011.00008

Rizzello, F. G., Guarino, A., Cimadoro, E., Salerno, V., and De Vito, V. (2010). In vivo evaluation of the impact of Bifidobacterium Bb-012 on the gut microbiota of healthy individuals. J. Nutr. Health Aging 14, 99–106. doi: 10.1007/s12603-009-0194-4

Ruiz et al. 2016, Volume 7 | Article 1193

Frontiers in Microbiology | www.frontiersin.org 9 August 2016

Frontiers in Microbiology | www.frontiersin.org 9 August 2016
Pokusaeva, R., Fitzgerald, G. F., and van Sinderen, D. (2011). Carbohydrate metabolism in Bifidobacteria. *Genes Nutr.* 6, 285–306. doi: 10.1007/s11263-010-0206-6

Pokusaeva, K., Neves, A. R., Zomer, A., O’Connell-Motherway, M., MacSharry, J., Curley, P., et al. (2010). Ribose utilization by the human commensal *Bifidobacterium* brev*UCC2003*. *Microb. Biotechnol.* 3, 311–323. doi: 10.1111/j.1751-7915.2009.00152

Pokusaeva, K., O’Connell-Motherway, M., Zomer, A., Fitzgerald, G. F., and van Sinderen, D. (2009). Characterization of two Novel α-glucosidases from *Bifidobacterium breve* UCC2003. *Appl. Environ. Microbiol.* 75, 1135–1143. doi: 10.1128/AEM.02391-08

Rastall, R. A., and Gibson, G. R. (2015). Recent developments in prebiotics to selectively impact beneficial microbes and promote intestinal health. *Curr. Opin. Biotechnol.* 32, 42–49. doi: 10.1016/j.copbio.2014.11.002

Ruiz-Moyano, S., Totten, S. M., Garrido, D. A., Smilowitz, J. T., Lebrilla, C. B., Mills, D. A., German, J. B., and Freeman, S. L. (2013). Metabiotics: novel idea or natural development of probiotics produced by infant gut-associated strains of *Bifidobacterium* as an example of a specialized human gut commensal. *Front. Microbiol.* 4:347. doi: 10.3389/fmicb.2013.00437

Turroni, F., Foroni, E., O’Connell-Motherway, M., Bottacini, F., Giubellini, V., and Zomer, A. (2010). Characterization of the serpin-encoding gene of *Bifidobacterium breve* brev210B. *Appl. Environ. Microbiol.* 76, 3206–3219. doi: 10.1128/AEM.02938-09

Turroni, F., Serafini, F., Foroni, E., Duranti, S., O’Connell-Motherway, M., and Taverniti, V. (2013). Role of sortase-dependent pilus of *Bifidobacterium bifidum* PRL2010 in modulating bacterium-host interactions. *Proc. Natl. Acad. Sci. U.S.A.* 110, 11151–11156. doi: 10.1073/pnas.130308 97110

Turroni, F., Strati, F., Foroni, E., Serafini, F., Duranti, S., van Sinderen, D., and Ventura, M. (2012). Analysis of predicted carbohydrate transport systems encoded by *Bifidobacterium bifidum* PRL2010. *Appl. Environ. Microbiol.* 78, 5002–5012. doi: 10.1128/AEM.00629-12

van der Waaij, L. A., Koese, F. G., Visser, A., Westerveld, B. D., Jansen, P. L., et al. (2004). Immunoglobulin coating of fecal bacteria in inflammatory bowel disease. *Eur. J. Gastroenterol. Hepatol.* 16, 669–674. doi: 10.1097/01.meg.0000108346.41221.19

Ventura, M., Turroni, F., Motherway, M. O. C., MacSharry, J., and van Sinderen, D. (2012). Host-microbe interactions that facilitate gut colonization by commensal bifidobacteria. *Trends Microbiol.* 20, 467–476. doi: 10.1016/j.tim.2012.07.002

Vilborg, A. H., Sorensen, K. L., Gilad, O., Steen-Jensen, D. B., Diokpinol, A. L., Jacobson, S., et al. (2013). Biochemical and kinetic characterization of a novel xylooligosaccharide-upregulated GH43 β-D-xylanase/α-L-arabinofuranosidase (BXA43) from the probiotic *Bifidobacterium animalis* subsp. lactis BB-12. *AMR Express* 3:56. doi: 10.1186/2091-0855-3-56

Vulic, J., Juric, A., Tzortzis, G., and Gibson, G. R. (2013). A mixture of trans-galactooligosaccharides reduces markers of metabolic syndrome and modulates the fecal microbiota and immune function of overweight adults. *J. Nutr.* 143, 324–331. doi: 10.1093/jn/njs166 132

Wada, J., Ando, T., Kiyohara, M., Ashida, H., Kitaoka, M., Yamaguchi, M., et al. (2008). *Bifidobacterium bifidum* lacto-N-biosidase, a critical enzyme for the degradation of human milk oligosaccharides with a Type 1 structure. *Appl. Environ. Microbiol.* 74, 3996–3904. doi: 10.1128/AEM.0149-08

Wada, J., Suzuki, R., Fushinobu, S., Kitaoka, M., Waki, T., Shoun, H., et al. (2007). Purification, crystallization and preliminary X-ray analysis of the galacto-N-biose/lacto-N-biose I-binding protein (GL-BP) of the ABC transporter from *Bifidobacterium longum* JCM11217. *Acta Crystallogr. Sect. F. Struct. Biol. Crystallogr. Commun.* 63(Pt 9), 751–753. doi: 10.1107/S0567739413008181

Wei, X., Guo, Y., Shao, C., Sun, Z., Zhurina, D., Liu, D., et al. (2012). Fructose uptake in *Bifidobacterium longum* NCC2705 is mediated by an ATP-binding cassette transporter. *J. Biol. Chem.* 287, 357–367. doi: 10.1074/jbc.M111.266213
Wei, X., Yan, X., Chen, X., Yang, Z., Li, H., Zou, D., et al. (2014). Proteomic analysis of the interaction of *Bifidobacterium longum* NCC2705 with the intestine cells Caco-2 and identification of plasminogen receptors. *J. Proteome Res.* 7, 373–385. doi: 10.1016/j.jprot.2014.04.038

Yoshida, E., Sakurama, H., Kiyohara, M., Nakajima, M., Kitaoka, M., Ashida, H., et al. (2012). *Bifidobacterium longum* subsp. *infantis* uses two different β-galactosidases for selectively degrading type-1 and type-2 human milk oligosaccharides. *Glycobiol.* 22, 361–368. doi: 10.1093/glycob/cwr116

Zelante, T., Fric, J., Wong, A. Y. W., and Ricciardi-Castagnoli, P. (2012). Interleukin-2 production by dendritic cells and its immuno-regulatory functions. *Front. Immunol.* 3:161. doi: 10.3389/fimmu.2012.00161

Zhao, J., and Cheung, P. C. (2013). Comparative proteome analysis of *Bifidobacterium longum* subsp. *infantis* grown on β-glucans from different sources and a model for their utilization. *J. Agric. Food Chem.* 61, 4360–4370. doi: 10.1021/jf400792j

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.